Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise
Executive Summary
Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.
You may also be interested in...
FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access
Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.
Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent
Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.
Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme
FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.